tiprankstipranks
Trending News
More News >
RELIEF THERAPEUTICS Holding (CH:RLF)
:RLF
Advertisement

RELIEF THERAPEUTICS Holding (RLF) Price & Analysis

Compare
1 Followers

RLF Stock Chart & Stats

CHF2.63
-CHF0.17(-5.52%)
At close: 4:00 PM EST
CHF2.63
-CHF0.17(-5.52%)

RELIEF THERAPEUTICS Holding News

RLF FAQ

What was RELIEF THERAPEUTICS Holding’s price range in the past 12 months?
RELIEF THERAPEUTICS Holding lowest stock price was CHF1.65 and its highest was CHF7.60 in the past 12 months.
    What is RELIEF THERAPEUTICS Holding’s market cap?
    RELIEF THERAPEUTICS Holding’s market cap is $33.10M.
      When is RELIEF THERAPEUTICS Holding’s upcoming earnings report date?
      RELIEF THERAPEUTICS Holding’s upcoming earnings report date is Apr 09, 2026 which is in 170 days.
        How were RELIEF THERAPEUTICS Holding’s earnings last quarter?
        RELIEF THERAPEUTICS Holding released its earnings results on Aug 29, 2025. The company reported -CHF0.357 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.357.
          Is RELIEF THERAPEUTICS Holding overvalued?
          According to Wall Street analysts RELIEF THERAPEUTICS Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does RELIEF THERAPEUTICS Holding pay dividends?
            RELIEF THERAPEUTICS Holding does not currently pay dividends.
            What is RELIEF THERAPEUTICS Holding’s EPS estimate?
            RELIEF THERAPEUTICS Holding’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does RELIEF THERAPEUTICS Holding have?
            RELIEF THERAPEUTICS Holding has 14,084,817 shares outstanding.
              What happened to RELIEF THERAPEUTICS Holding’s price movement after its last earnings report?
              RELIEF THERAPEUTICS Holding reported an EPS of -CHF0.357 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.23%.
                Which hedge fund is a major shareholder of RELIEF THERAPEUTICS Holding?
                Currently, no hedge funds are holding shares in CH:RLF

                Company Description

                RELIEF THERAPEUTICS Holding

                Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

                RELIEF THERAPEUTICS Holding (RLF) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Molecular Partners AG
                Basilea Pharmaceutica
                Idorsia Ltd
                Newron Pharmaceuticals SpA
                Santhera Pharmaceuticals Holding

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis